BioSpace News Archive

Business

Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the third quarter ended September 30, 2022, and provided a clinical and corporate update.

November 10, 2022
·
14 min read
Business

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

Monte Rosa Therapeutics, Inc. today reported business highlights and financial results for the third quarter, ended September 30, 2022.

November 10, 2022
·
9 min read
Business

Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Sigilon Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2022 as well as certain other business highlights.

November 10, 2022
·
11 min read
Business

TG Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2022 and recent company developments, along with a business outlook for the remainder of 2022.

November 10, 2022
·
9 min read
Business

IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced financial results, corporate developments, and operational highlights for the third quarter ended September 30, 2022.

November 10, 2022
·
10 min read
Business

Wave Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Wave Life Sciences Ltd., a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced financial results for the third quarter ended September 30, 2022 and provided a business update.

November 10, 2022
·
20 min read
Business

Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today reported financial results for the third quarter ended September 30, 2022 and provided a business update.

November 10, 2022
·
14 min read
Biotech Bay

Medable Named Leader in Decentralized Clinical Trial Products Assessment for Second Consecutive Year by Everest Group

Medable Inc. today announced that it was named a Leader in the “Decentralized Clinical Trial Products PEAK Matrix® Assessment 2022” by Everest Group for the second consecutive year.

November 10, 2022
·
4 min read
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

Myriad Genetics, Inc. today announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care.

November 10, 2022
·
3 min read
Business

Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today reported financial results for the third quarter ended September 30, 2022.

November 10, 2022
·
14 min read